ResultsIQ

ResultsIQ › Latest results › Anthem Biosciences Limited

Anthem Biosciences Limited Q1 FY27 results deck summary

NSE: ANTHEM · BSE: 544449

Results deck of 21 Jul 2026, summarised by AI from the filing.

Q1FY27 revenue ₹4,182 Mn (-22.6% YoY), EBITDA margin 39.6%, PAT ₹1,199 Mn; management expects to sustain growth through the year.

Key takeaways

  1. Guidance Management expects to sustain revenue growth and margin performance through the year.
  2. Change Revenue declined 31.5% quarter-on-quarter from ₹6,109 Mn in Q4FY26.
  3. Driver Underlying demand remains strong with higher concentration of scheduled deliveries in H2.
  4. Risk Timing shifts in deliveries to key customers affected quarterly revenue.

Original filing on BSE

Anthem Biosciences Limited Q1 FY27 results

As filed: Revenue ₹418 cr (−23% year on year), EBITDA ₹151 cr (−21% year on year), PAT ₹120 cr (−12% year on year), EBITDA margin 36.0% (+63 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹583 cr, EBITDA ₹267 cr, PAT ₹212 cr, EBITDA margin 45.8%. Not scored. No result for the same quarter last year. Share price after the results: +1.4% in 30 days (Nifty 500: +3.0%).
  • Q3 FY26: Revenue ₹417 cr, EBITDA ₹163 cr, PAT ₹112 cr, EBITDA margin 39.1%. Not scored. No result for the same quarter last year. Share price after the results: +21.1% in 30 days (Nifty 500: +2.8%).
  • Q2 FY26: Revenue ₹552 cr, EBITDA ₹225 cr, PAT ₹198 cr, EBITDA margin 40.8%. Not scored. No result for the same quarter last year. Share price after the results: −6.8% in 30 days (Nifty 500: 0.0%).
  • Q1 FY26: Revenue ₹538 cr, EBITDA ₹196 cr, PAT ₹148 cr, EBITDA margin 36.4%. Not scored. No result for the same quarter last year. Share price after the results: +10.4% in 30 days (Nifty 500: +2.2%).

Past price moves after results do not indicate future moves. Not a recommendation.

Anthem Biosciences Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.